Facebook Tracking Image

National Comprehensive Cancer Network

About NCCN

NCCN Foundation YIA Recipient Reports CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer, Manuscript Published in NEJM

A study published in The New England Journal of Medicine on January 21, 2016 shows that the disease-free survival rates of patients with stage II and stage III colon cancer without CDX2 expression were increased with administration of adjuvant chemotherapy. Moreover, researchers found that patients with CDX2-negative stage II colon cancer—who are typically treated with surgery alone—could benefit from chemotherapy after surgery, and advocated for their findings to be further confirmed in randomized clinical trials.

The study, titled, “CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer,” was funded, in part, by the NCCN Foundation® Young Investigator Awards (YIA). Lead author, Piero D. Dalerba, MD, Assistant Professor, Department of Pathology and Cell Biology, Department of Medicine (Division of Digestive and Liver Diseases), Herbert Irving Comprehensive Cancer Center at Columbia University, was a 2012 YIA grant recipient.

Formerly Instructor of Medicine at Stanford Cancer Institute, Dr. Dalerba was awarded $150,000 in 2012 by the NCCN Foundation to study CDX2 as a novel predictive biomarker to guide therapeutic algorithm design in colon cancer.

“The further identification of prognostic biomarkers in patients with cancer is imperative to the advancement of the science of oncology in order to provide effective, personalized medicine,” said Dr. Dalerba. “My colleagues and I are immensely thankful for this opportunity; the NCCN Foundation YIA was absolutely key to the success of this study and my professional career.”

Each year the NCCN Foundation invites young researchers from the NCCN Member Institutions to propose study ideas related to advancing and discovering new treatments for cancer. Through this initiative, the NCCN Foundation trains the next generation of clinical experts and supports high-quality research and innovation in oncology.

“The NCCN Foundation is committed to the advancement of cancer treatment through funding promising young investigators at the forefront of innovation in cancer research,” said Marcie Reeder, MPH, Executive Director, NCCN Foundation. “We applaud Dr. Dalerba and his colleagues on their research and publication.”

For more information about NCCN Foundation YIA, visit NCCNFoundation.org